J&J axes its big BACE program in asymptomatic Alzheimer's patients as the drumbeat of PhIII failures rolls on
Researchers at J&J $JNJ have pulled the plug on yet another BACE program for Alzheimer’s.
Unlike Merck, which scrapped their leading BACE program for verubecestat after it clearly failed to help patients on cognition and function in a major Phase III study, J&J was forced to halt the Phase IIb/III trial of atabecestat (JNJ-54861911) after some of the patients in the drug arm began to demonstrate serious spikes in liver enzymes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.